Abstract:Unhealthy lifestyle habits including a sedentary life, the lack of physical activity, and wrong dietary habits are the major ones responsible for the constant increase of obesity and metabolic disorders prevalence worldwide; therefore, the scientific community pays significant attention to the pharmacotherapy of such diseases, beyond lifestyle interventions, the use of medical devices, and surgical approaches. The intricate interplay between autophagy and inflammation appears crucial to orchestrate fundamental aspects of cellular and organismal responses to challenging stimuli, including metabolic insults; hence, when these two processes are dysregulated (enhanced or suppressed) they produce pathologic effects. The present review summarizes the existing literature reporting the intricate affair between autophagy and inflammation in the context of metabolic disorders, including obesity, diabetes, and liver metabolic diseases (non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)). The evidence collected so far suggests that an alteration of autophagy might lead to maladaptive metabolic and inflammatory responses thus exacerbating the severity of the disease, and the most prominent conclusion underlies that autophagy might exert a protective function by contributing to balance inflammation. However, the complex nature of obesity and metabolic disorders might represent a limit of the studies; indeed, although many pharmacological treatments, producing positive metabolic effects, are also able to modulate autophagic flux and inflammation, it is not clear if the final beneficial effect might occur only by their mechanism of action, rather than because of additionally involved pathways. Finally, although future studies are needed, the observation that anti-obesity and antidiabetic drugs already on the market, including incretin mimetic agents, facilitate autophagy by dampening inflammation, strongly contributes to the idea that autophagy might represent a druggable system for the development of novel pharmacological tools that might represent an attractive strategy for the treatment of obesity and metabolic disorders.

Targeting Autophagy in the Management of Obesity and Metabolic Diseases

Targeting Autophagy in Obesity: from Pathophysiology to Management.

Autophagy as an emerging target in cardiorenal metabolic disease: From pathophysiology to management

Regulation of Autophagy in Obesity-Induced Cardiac Dysfunction

Unmasking the janus faces of autophagy in obesity-associated insulin resistance and cardiac dysfunction.

Targeting Autophagy in Aging and Aging-Related Cardiovascular Diseases

Metabolic Stress, Autophagy, and Cardiovascular Aging: from Pathophysiology to Therapeutics

Research advance in autophagy in obesity

Autophagic Regulation of Lipid Homeostasis in Cardiometabolic Syndrome

Autophagy and inflammation an intricate affair in the management of obesity and metabolic disorders: evidence for novel pharmacological strategies?

The engagement of autophagy in maniac disease.

The role of autophagy in cardiovascular disease: Cross-interference of signaling pathways and underlying therapeutic targets

Current Status of Autophagy Enhancers in Metabolic Disorders and Other Diseases

Role of Autophagy in Inherited Metabolic and Endocrine Myopathies

Autophagy in Adipocyte Browning: Emerging Drug Target for Intervention in Obesity

Dysfunctional Mitochondria Clearance in Situ: Mitophagy in Obesity and Diabetes-Associated Cardiometabolic Diseases

Targeting Autophagy in Diabetic Cardiomyopathy: from Molecular Mechanisms to Pharmacotherapy

Autophagy And Cardiac Diseases: Therapeutic Potential Of Natural Products

Epigenetic and post-translational modifications in autophagy: biological functions and therapeutic targets

Relationship Between Autophagy and Metabolic Syndrome Characteristics in the Pathogenesis of Atherosclerosis

Mitophagy Receptors and Mediators: Therapeutic Targets in the Management of Cardiovascular Ageing.